Highlights JW (Cayman) Therapeutics Co. Ltd

Equities

2126

KYG5210T1040

Delayed Hong Kong S.E. Other stock markets 04:08:22 2024-04-29 am EDT			5-day change	1st Jan Change
1.82 ^HKD	+7.06%		+5.81%	-19.47%

Mar. 20	JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023	MT
Mar. 20	JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023	Mar. 20	MT
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
China Regulator Accepts JK Therapeutics' Supplemental License Application for Lymphoma Therapy	Jan. 04	MT
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva in Patients with Relapsed or Refractory Mantle Cell Lymphoma	Jan. 04	CI
JW Therapeutics Announces Exclusive Collaboration with 2Seventy Bio for Autoimmune Disease Car-T Therapy	Jan. 02	CI
JW (Cayman) Therapeutics to Expand Strategic Alliance with Cell and Gene Therapy Firm	23-09-13	MT
2Seventy Bio, Inc. and Jw Therapeutics Announce Intent to Expand Strategic Partnership to Accelerate the Research and Development of T Cell-Based Immunotherapies and Autoimmune Therapies	23-09-12	CI
JW Therapeutics' H1 Attributable Loss Narrows on Higher Revenue	23-08-29	MT
JW Therapeutics Co. Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
JW (Cayman) Therapeutics to Buy Viral Vector from Substantial Shareholder	23-05-22	MT
JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus	23-04-10	CI
JW Therapeutics' 2022 Loss Widens	23-03-30	MT
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
JW Therapeutics Co. Ltd. Announces Initiation of Clinical Study of Carteyva® in First-Line Treatment in Patients with High-Risk Large B-Cell Lymphoma	23-03-08	CI
JW Therapeutics Co. Ltd Announces the Initiation of Clinical Study of JWATM214	23-02-28	CI
JW Therapeutics Co. Ltd Provides Update on Latest Clinical Data on Carteyva® in Follicular Lymphoma	22-12-12	CI
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients	22-11-09	CI
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies	22-10-27	CI
JW (Cayman) Therapeutics to Develop, Market 2seventy bio's Cell Therapy Product in China	22-10-26	MT
JW (Cayman) Gets Regulatory OK in China for Supplemental New Drug Application for Follicular Lymphoma Treatment	22-10-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights JW (Cayman) Therapeutics Co. Ltd

Equities

2126

KYG5210T1040

Highlights

Filters